Jianke

About Jianke

Fangzhou Inc. (方舟健客, 6086.HK), operating under the brand Jianke, is a prominent online platform in China focused on managing chronic diseases. The company was established in 2015, with its holding company, Fangzhou Inc., incorporated in 2019. It was founded by Xie Fangmin, who serves as the Chairman and CEO. Xie has a strong background in internet operations, which he has leveraged to combine e-commerce models with the health industry, creating the company's H2H (Hospital-to-Home) service platform.

The company's core business revolves around providing comprehensive services for individuals with chronic conditions such as hypertension, cardiovascular diseases, and respiratory illnesses. Its business model is segmented into three main areas: comprehensive medical services, online retail pharmacy services, and customized content and marketing solutions. Revenue is primarily generated through the online sale of prescription drugs, which accounts for over 80% of its income. The platform connects patients with registered physicians for follow-up consultations and e-prescriptions. Following a consultation, users can purchase a wide array of pharmaceuticals and healthcare products directly through the Jianke online retail pharmacy, which are then delivered to their homes. Additionally, the company offers marketing and content solutions to pharmaceutical companies, helping them to better inform both doctors and patients about chronic diseases and treatment options.

The Jianke platform has cultivated a substantial user base, reporting an average of 8.4 million monthly active users and 42.7 million registered users by the end of 2023. It also boasts a large network of nearly 223,000 registered physicians. The company has embraced technology, integrating AI and big data to offer personalized health management plans and enhance the efficiency of its services. In March 2025, Jianke announced a strategic collaboration with Tencent Health and Tencent Cloud to further develop its AI-driven healthcare solutions. After several attempts, the company successfully launched its Initial Public Offering on the Hong Kong Stock Exchange on July 9, 2024, raising approximately HK$195 million.